Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.43
$0.030.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.11% | 0.47% | 5.73% | 0.51% | 32.86% |
| Total Depreciation and Amortization | -3.09% | -0.38% | -0.38% | 0.38% | -7.14% |
| Total Amortization of Deferred Charges | 140.91% | 3.13% | -1.54% | 1.56% | 8.47% |
| Total Other Non-Cash Items | -12.88% | 22.51% | -39.63% | 68.92% | -58.20% |
| Change in Net Operating Assets | -569.31% | 24.63% | -43.28% | 127.40% | -141.33% |
| Cash from Operations | -2.17% | 3.82% | -2.72% | 25.51% | -20.45% |
| Capital Expenditure | 27.27% | 38.89% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.12% | -1.34% | 97.10% | -40.14% | -26.80% |
| Cash from Investing | -42.12% | -1.31% | 96.95% | -40.14% | -26.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,874.47% | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | 106.67% | -568.75% | 433.33% | 142.86% | -118.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -168.89% | 4.69% | 238.39% | -93.25% | -127.36% |